Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.
Also called NCT02044653
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 257 participants
- Sponsor
- Genexine, Inc.
- Registry
-
NCT02044653
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02044653. Randomized; single masking; primary purpose treatment. Start 2014-04-15 (actual); primary completion 2017-04-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
- Condition
- Anemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- GX-E2
- Intervention (Drug)
- GX-E2
- Intervention (Drug)
- GX-E2
- Intervention (Drug)
- NESP
- Intervention (Drug)
- MIRCERA
- Lead sponsor
- Genexine, Inc.
Record details
- Record id
cardio:ct-nct02044653- Content hash
8a51b212bcb8f03595a9d565cd5c3d737de4691609025ffd52402ce7707b0580